Timothy A. Riley, Ph.D.
Emotionally intelligent, entrepreneurial Executive in the pharmaceutical and biotechnology industry with multiple drugs approved and approaching approval. These products are projected to be multi-billion dollar products and have created over $1.5 billion in market capitalization. Built and led successful teams in pharmaceutical research and development with over three decades of experience. Leadership positions include Executive position in business development for a top tier research medical school, decade long tenure as Executive Committee member of a publicly traded company, SVP of Global Research, and SVP of Quality. Directed internal and external international relationships. Therapeutic areas include Rare Diseases, Hemophilia, Pain, Oncology, Antivirals. Areas of technical expertise: large molecules including oligonucleotides, peptides and proteins; small molecules including heterocycles, nucleosides, carbohydrates as well as retooling or rescue of existing drugs with lipid and PEG technologies. Co-founded a target validation company, linking genes to their importance in disease. Proven ability to influence investors to make financial commitments to new entities. Successfully interfaced with finance, biology, chemistry, clinical, regulatory, QA, manufacturing, and business development functions.